Mizuho has increased its price target for Amgen (NASDAQ: AMGN) to $295 from $280, while maintaining an Outperform rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Amgen’s financial prospects. The date of publication for this analyst action was February 10, 2026, at 10:07 am EST.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating
Mizuho has increased its price target for Amgen (NASDAQ: AMGN) to $295 from $280, while maintaining an Outperform rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Amgen’s financial prospects. The date of publication for this analyst action was February 10, 2026, at 10:07 am EST.